J Rheum Dis 2018; 25(2): 144-147  
Patient with Systemic Lupus Erythematosus Combined with Erosive Arthritis was Treated Successfully with Tocilizumab: A Case Report
Moon Young Kim1, Sunghoon Park2, Chang-Hee Suh1, Ju-Yang Jung1, Hyoun-Ah Kim1
Departments of 1Rheumatology and 2Radiology, Ajou University School of Medicine, Suwon, Korea
Correspondence to: Hyoun-Ah Kim http://orcid.org/0000-0003-2609-3367
Department of Rheumatology, Ajou University School of Medicine, 164 WorldCup-ro, Yeongtong-gu, Suwon 16499, Korea.
Received: August 11, 2017; Revised: August 29, 2017; Accepted: October 25, 2017; Published online: April 1, 2018.
© Korean College of Rheumatology. All rights reserved.

This is a open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Systemic lupus erythematosus (SLE) is a systemic autoimmune inflammatory disease that frequently involves the joints at some stage during the disease course. Although lupus arthritis is usually non-erosive, approximately 5% of patients develop erosions. This paper reports a patient with SLE combined with erosive arthritis, who was treated successfully with tocilizumab. A 20-year-old female, who was first diagnosed with SLE at the age of 13 years, had been admitted frequently to hospital with disease flare-ups during the previous 3 years. Despite aggressive treatment, her arthritis became aggravated, particularly in both wrists and the right knee. Radiologically, erosive arthritis was noted in the wrists.The serum interleukin (IL)-6 level was elevated significantly along with the other inflammatory markers. After the tocilizumab treatment, the arthritis subsided with a normalization of the IL-6 level, suggesting that tocilizumab may be a suitable treatment for lupus erosive arthritis if the IL-6 level is high.
Keywords: Systemic lupus erythematosus, Arthritis, Interleukin-6 inhibitor, Interleukin-6

This Article